PVLA Reports Phase 2 TOIVA: 100% Bleeding Improvement, +2.5 cVM-IGA Score in 4 Patients
Palvella Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $112.59
-8.0% in 1d after detection
Post-detection moves
1h
—
1d
-8.0%
3d
+1.1%
7d
+1.8%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS